S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:AYLA

Ayala Pharmaceuticals Stock Forecast, Price & News

$13.41
+0.40 (+3.07 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.01
Now: $13.41
$14.03
50-Day Range
$12.29
MA: $15.75
$22.00
52-Week Range
$8.62
Now: $13.41
$28.68
Volume8,051 shs
Average Volume45,990 shs
Market Capitalization$171.37 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was founded in 2017 and is based in Rehovot, Israel.
Ayala Pharmaceuticals logo

Headlines

Ayala Pharmaceuticals raises $25M from private stock sale
February 24, 2021 |  bizjournals.com
Ayala Pharmaceuticals Inc
December 16, 2020 |  reuters.com
Ayala Pharmaceuticals to host KOL event on September 18
September 14, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AYLA
CUSIPN/A
CIKN/A
Phone857-444-0553
Employees31
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.33 million

Profitability

Net Income$-17,790,000.00
Net Margins-850.81%

Miscellaneous

Market Cap$171.37 million
Next Earnings Date3/9/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.47 out of 5 stars

Medical Sector

540th out of 1,972 stocks

Biological Products, Except Diagnostic Industry

77th out of 177 stocks

Analyst Opinion: 3.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$13.41
+0.40 (+3.07 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AYLA News and Ratings via Email

Sign-up to receive the latest news and ratings for AYLA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ayala Pharmaceuticals (NASDAQ:AYLA) Frequently Asked Questions

Is Ayala Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ayala Pharmaceuticals stock.
View analyst ratings for Ayala Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Ayala Pharmaceuticals?

Wall Street analysts have given Ayala Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ayala Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Ayala Pharmaceuticals' next earnings date?

Ayala Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Ayala Pharmaceuticals
.

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) issued its quarterly earnings results on Tuesday, November, 17th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.55) by $0.04. The business had revenue of $0.66 million for the quarter, compared to the consensus estimate of $1.05 million. Ayala Pharmaceuticals had a negative trailing twelve-month return on equity of 625.24% and a negative net margin of 850.81%.
View Ayala Pharmaceuticals' earnings history
.

What price target have analysts set for AYLA?

6 brokers have issued 12 month price targets for Ayala Pharmaceuticals' stock. Their forecasts range from $20.00 to $29.00. On average, they expect Ayala Pharmaceuticals' share price to reach $24.20 in the next year. This suggests a possible upside of 80.5% from the stock's current price.
View analysts' price targets for Ayala Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Ayala Pharmaceuticals' key executives?

Ayala Pharmaceuticals' management team includes the following people:
  • Dr. Roni Mamluk, Pres, CEO & Director (Age 54, Pay $390.57k)
  • Mr. Yossi Maimon CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 50, Pay $424.88k)
  • Dr. Gary B. Gordon M.D., Ph.D., Chief Medical Officer (Age 68, Pay $323.26k)

Who are some of Ayala Pharmaceuticals' key competitors?

What other stocks do shareholders of Ayala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Moderna (MRNA), CrowdStrike (CRWD), Dynavax Technologies (DVAX), Square (SQ), Abbott Laboratories (ABT), Alpine Immune Sciences (ALPN), Advanced Micro Devices (AMD), BioLineRx (BLRX), Cognex (CGNX) and Micron Technology (MU).

When did Ayala Pharmaceuticals IPO?

(AYLA) raised $50 million in an initial public offering on Friday, May 8th 2020. The company issued 3,300,000 shares at a price of $14.00-$16.50 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Oppenheimer and Raymond James were co-managers.

What is Ayala Pharmaceuticals' stock symbol?

Ayala Pharmaceuticals trades on the NASDAQ under the ticker symbol "AYLA."

How do I buy shares of Ayala Pharmaceuticals?

Shares of AYLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ayala Pharmaceuticals' stock price today?

One share of AYLA stock can currently be purchased for approximately $13.41.

How much money does Ayala Pharmaceuticals make?

Ayala Pharmaceuticals has a market capitalization of $171.37 million and generates $2.33 million in revenue each year.

How many employees does Ayala Pharmaceuticals have?

Ayala Pharmaceuticals employs 31 workers across the globe.

What is Ayala Pharmaceuticals' official website?

The official website for Ayala Pharmaceuticals is www.ayalapharma.com.

Where are Ayala Pharmaceuticals' headquarters?

Ayala Pharmaceuticals is headquartered at Oppenheimer 4, Rehovot L3, 7670104.

How can I contact Ayala Pharmaceuticals?

Ayala Pharmaceuticals' mailing address is Oppenheimer 4, Rehovot L3, 7670104. The company can be reached via phone at 857-444-0553 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.